Why Palisade Bio Stock Is Soaring Today
Palisade Bio shares are trading higher Tuesday after the company announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108. Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ulcerative colitis (UC). The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.